Pulmatrix (DB:2PU) - Stock Price, News & Analysis

2PU Stock Overview

A clinical stage biotechnology company, focused on development of novel inhaled therapeutic products to prevent and treat respiratory and other diseases with unmet medical needs in the United States. More details

2PU fundamental analysis
Snowflake Score
Valuation	2/6
Future Growth	0/6
Past Performance	0/6
Financial Health	4/6
Dividends	0/6

Rewards

Earnings have grown 9.2% per year over the past 5 years

Risk Analysis

Highly volatile share price over the past 3 months compared to the German market

Has less than 1 year of cash runway

Does not have a meaningful market cap (€22M)

Pulmatrix, Inc. Competitors

Biofrontera

XTRA:B8FK

€16.4m

SynBiotic

DUSE:SBX

€27.9m

Redx Pharma

DB:0RX

€65.0m

Cantourage Group

XTRA:HIGH

€55.6m

Price History & Performance

Summary of all time highs, changes and price drops for Pulmatrix
Historical stock prices
Current Share Price	US$5.75
52 Week High	US$7.30
52 Week Low	US$1.41
Beta	0.99
11 Month Change	223.03%
3 Month Change	221.23%
1 Year Change	247.22%
33 Year Change	-48.75%
5 Year Change	-61.15%
Change since IPO	-99.14%

Recent updates

Shareholder Returns

	2PU	DE Pharmaceuticals	DE Market
7D	31.9%	-5.0%	-1.3%
1Y	247.2%	-22.0%	7.4%

Return vs Industry: 2PU exceeded the German Pharmaceuticals industry which returned -22% over the past year.

Return vs Market: 2PU exceeded the German Market which returned 7.4% over the past year.

Price Volatility

Is 2PU's price volatile compared to industry and market?
2PU volatility
2PU Average Weekly Movement	31.3%
Pharmaceuticals Industry Average Movement	6.9%
Market Average Movement	4.8%
10% most volatile stocks in DE Market	10.8%
10% least volatile stocks in DE Market	2.4%

Stable Share Price: 2PU's share price has been volatile over the past 3 months compared to the German market.

Volatility Over Time: 2PU's weekly volatility has increased from 17% to 31% over the past year.

About the Company

Founded	Employees	CEO	Website
2003	22	Peter Ludlum	www.pulmatrix.com

Pulmatrix, Inc., a clinical stage biotechnology company, focused on development of novel inhaled therapeutic products to prevent and treat respiratory and other diseases with unmet medical needs in the United States. The company offers iSPERSE, an engineered dry powder delivery platform, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications. It engages in developing PUR1800, a narrow spectrum kinase inhibitor completed Phase 1b clinical trials for the treatment of acute exacerbations in chronic obstructive pulmonary disease; PUR1900 for the treatment of allergic bronchopulmonary aspergillosis in patients with asthma and cystic fibrosis; and PUR3100, an iSPERSE formulation of dihydroergotamine which is in Phase 1 for the treatment of acute migraine.

Pulmatrix, Inc. Fundamentals Summary

How do Pulmatrix's earnings and revenue compare to its market cap?
2PU fundamental statistics
Market cap	€21.43m
Earnings (TTM)	-€9.27m
Revenue (TTM)	€9.61m

2.2x

P/S Ratio

-2.3x

P/E Ratio

Is 2PU overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
2PU income statement (TTM)
Revenue	US$10.01m
Cost of Revenue	US$10.68m
Gross Profit	-US$671.00k
Other Expenses	US$8.99m
Earnings	-US$9.66m

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)	-2.64
Gross Margin	-6.71%
Net Profit Margin	-96.51%
Debt/Equity Ratio	0%

How did 2PU perform over the long term?

See historical performance and comparison

2PU Stock Overview

Rewards

Risk Analysis

Pulmatrix, Inc. Competitors

XTRA:B8FK

€16.4m

DUSE:SBX

€27.9m

DB:0RX

€65.0m

XTRA:HIGH

€55.6m

Price History & Performance

Recent News & Updates

Cullgen Inc. entered into an Agreement to acquire Pulmatrix, Inc. (NasdaqCM:PULM) in a reverse merger transaction

Cullgen Inc. entered into an Agreement to acquire Pulmatrix, Inc. (NasdaqCM:PULM) in a reverse merger transaction

New major risk - Share price stability

Cullgen Inc. entered into an Agreement to acquire Pulmatrix, Inc. (NasdaqCM:PULM) in a reverse merger transaction

Third quarter 2024 earnings released: US$0.71 loss per share (vs US$1.03 loss in 3Q 2023)

Pulmatrix, Inc., Annual General Meeting, Dec 18, 2024

Recent updates

Cullgen Inc. entered into an Agreement to acquire Pulmatrix, Inc. (NasdaqCM:PULM) in a reverse merger transaction

Cullgen Inc. entered into an Agreement to acquire Pulmatrix, Inc. (NasdaqCM:PULM) in a reverse merger transaction

New major risk - Share price stability

Cullgen Inc. entered into an Agreement to acquire Pulmatrix, Inc. (NasdaqCM:PULM) in a reverse merger transaction

Third quarter 2024 earnings released: US$0.71 loss per share (vs US$1.03 loss in 3Q 2023)

Pulmatrix, Inc., Annual General Meeting, Dec 18, 2024

Second quarter 2024 earnings released: US$1.59 loss per share (vs US$1.05 loss in 2Q 2023)

Pulmatrix Announces Peer-Reviewed Publication of Clinical Results for its Orally Inhaled Dhe for Acute Migraine (PUR3100)

First quarter 2024 earnings released: EPS: US$0.23 (vs US$1.22 loss in 1Q 2023)

Full year 2023 earnings released: US$3.87 loss per share (vs US$5.46 loss in FY 2022)

Pulmatrix, Inc. Enters into Further Amendment to Its Agreement with Cipla for the Development of PUR1900 in the Treatment of Allergic Bronchopulmonary Aspergillosis

Insufficient new directors

New minor risk - Share price stability

Pulmatrix, Inc. Announces Publication on Physiologically Based Pharmacokinetic Modelling of Potential Drug-Drug Interactions with PUR1900, Orally Inhaled Itraconazole

Second quarter 2023 earnings released: US$1.05 loss per share (vs US$1.36 loss in 2Q 2022)

Pulmatrix, Inc. Announces Submission of IND Application to FDA to Initiate a Phase 2 Trial of Investigational Drug PUR3100 to Treat Acute Migraine

Pulmatrix, Inc., Annual General Meeting, Jul 13, 2023

First quarter 2023 earnings released: US$1.22 loss per share (vs US$1.51 loss in 1Q 2022)

Full year 2022 earnings released: US$5.46 loss per share (vs US$8.63 loss in FY 2021)

Pulmatrix Announces First Patient Dosed in Phase 2b Study of PUR1900 for Treatment of Allergic Bronchopulmonary Aspergillosis (ABPA) in Subjects with Asthma

Pulmatrix, Inc. Announces Positive Top Line Results from a Phase 1 Study with PUR3100, a Novel Orally Inhaled Dihydroergotamine (DHE), for Acute Migraine

Third quarter 2022 earnings released: US$1.45 loss per share (vs US$2.91 loss in 3Q 2021)

Pulmatrix, Inc. Announces Patient Dosing Completed for Its Novel Inhaled Therapy PUR3100 for Acute Migraine

Second quarter 2022 earnings released: US$1.36 loss per share (vs US$1.37 loss in 2Q 2021)

Pulmatrix, Inc. Announces First Subject Dosed in Phase 1 Study of PUR3100 for Acute Migraine

First quarter 2022 earnings released: US$1.51 loss per share (vs US$1.78 loss in 1Q 2021)

Pulmatrix, Inc., Annual General Meeting, Jun 15, 2022

No longer forecast to breakeven

Pulmatrix Appoints Peter Ludlum as Interim Chief Financial Officer

No longer forecast to breakeven

Full year 2021 earnings released: US$8.63 loss per share (vs US$13.43 loss in FY 2020)

Pulmatrix, Inc. Appoints Dr. Margaret Wasilewski as Chief Medical Officer

Forecast to breakeven in 2024

Third quarter 2021 earnings released: US$0.14 loss per share (vs US$0.31 loss in 3Q 2020)

Pulmatrix Receives A Letter from the Listing Qualifications Department of the Nasdaq Stock Market

Second quarter 2021 earnings released: US$0.068 loss per share (vs US$0.048 loss in 2Q 2020)

Independent Director Mark Iwicki has left the company

First quarter 2021 earnings released: US$0.089 loss per share (vs US$0.23 loss in 1Q 2020)

Independent Director has left the company

Full year 2020 earnings released: US$0.67 loss per share (vs US$1.23 loss in FY 2019)

Pulmatrix Provides Pipeline and Business Update

New 90-day high: €1.41

New 90-day high: €1.17

New 90-day high: €1.15

Revenue in line with expectations

Third quarter 2020 earnings released: US$0.31 loss per share

Pulmatrix, Inc. Appoints Todd Bazemore to Its Board of Directors, Effective October 1, 2020

Pulmatrix, Inc. Provides an Update on Product Pipeline

Shareholder Returns

Price Volatility

About the Company

Pulmatrix, Inc. Fundamentals Summary

2.2x

-2.3x

Earnings & Revenue